ARS Pharmaceuticals (NASDAQ:SPRY) Stock Moved Down to “Outperform” by Raymond James Financial

Raymond James Financial cut shares of ARS Pharmaceuticals (NASDAQ:SPRY) from a strong-buy rating to an outperform rating in a report issued on Friday morning, MarketBeat.com reports.

A number of other brokerages also recently commented on SPRY. Weiss Ratings downgraded ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Leerink Partners set a $15.00 target price on shares of ARS Pharmaceuticals in a report on Tuesday, September 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

ARS Pharmaceuticals Stock Up 5.3%

Shares of NASDAQ SPRY traded up $0.14 during mid-day trading on Friday, hitting $2.79. The company had a trading volume of 5,672,082 shares, compared to its average volume of 1,668,914. The company has a market capitalization of $277.47 million, a PE ratio of -1.38 and a beta of 0.98. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. ARS Pharmaceuticals has a 1-year low of $2.44 and a 1-year high of $13.15. The business’s 50-day simple moving average is $4.29 and its 200 day simple moving average is $7.22.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.06). The company had revenue of $37.71 million for the quarter, compared to analyst estimates of $41.99 million. ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%. On average, analysts predict that ARS Pharmaceuticals will post -1.91 earnings per share for the current year.

Institutional Investors Weigh In On ARS Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. FAS Wealth Partners Inc. raised its holdings in ARS Pharmaceuticals by 1.5% during the first quarter. FAS Wealth Partners Inc. now owns 205,407 shares of the company’s stock worth $1,649,000 after purchasing an additional 3,000 shares in the last quarter. Bessemer Group Inc. raised its stake in ARS Pharmaceuticals by 3,102.1% during the 1st quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock worth $61,000 after acquiring an additional 7,290 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in ARS Pharmaceuticals by 46.1% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 31,568 shares of the company’s stock worth $253,000 after acquiring an additional 9,954 shares in the last quarter. Alpine Woods Capital Investors LLC acquired a new stake in ARS Pharmaceuticals during the 1st quarter worth $80,000. Finally, USAdvisors Wealth Management LLC purchased a new stake in ARS Pharmaceuticals in the third quarter valued at $43,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Key Stories Impacting ARS Pharmaceuticals

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Positive Sentiment: ARS said neffy’s U.S. market share has surpassed 5% and is targeting cash-flow breakeven by year-end 2027, offering investors signs of product adoption and a longer-term financial milestone. Article: ARS targets cash-flow breakeven as neffy share surpasses 5%
• Neutral Sentiment: Raymond James cut its rating from Strong Buy to Outperform but maintained a $17 price target. The downgrade may temper sentiment, though the firm’s revised rating remains positive. Article: Raymond James rating and price target
• Negative Sentiment: Third-quarter results fell short of expectations: ARS reported a $0.36-per-share loss versus an approximately $0.30 consensus loss, while revenue of $37.71 million missed the $41.99 million estimate. The shortfall could weigh on near-term sentiment. Article: ARS reports Q3 loss and misses revenue estimates

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.